Evaluation of Laser and Tranexamic Acid in Treatment of Melasma

Launched by ASSIUT UNIVERSITY · Oct 17, 2020

Keywords

ClinConnect Summary

Many studies examined multiple treatment options for melasma , but none of them is completely satisfactory with recurrence in most cases.

Tranexamic acid is is a relatively new drug for melasma . It is currently used via a spectrum of delivery routes including oral, topical, intradermal, and microneedling .

Laser-assisted drug delivery (LADD) is a technique that facilitates the delivery of topical medications .

On reviewing the previous literatures, few studies have focused on therapeutic effects of combined laser and TXA (topical and intradermal) in melasma, with variations in parameter...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • - Gender: Only female patients.
• • Age: 18-50 years old.
• • Type of melasma: Bilateral symmetrical facial melasma of all types.
• • Fitzpatrick skin phototypes: Types III, IV and V.
• Exclusion Criteria:
• • - Pregnancy and lactation.
• • Patients taking oral contraceptive pills, hormonal replacement therapy or isotretinoin at the time of the study or during the past 6 months. Concomitant use of anticoagulants, bleeding disorders.
• • Scarring and keloid tendency, active skin infections, active HSV, and those with facial cancer.
• • History of photosensitivity or photosensitizing medications such as sulfonamides and tetracycline.
• • Previous history of post inflammatory hyperpigmentation.